Progression-Free Survival and Time to Progression as Potential Surrogate Endpoints for Overall Survival in Chemoradiotherapy Trials in Limited-Stage Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis

PURPOSE: To investigate whether progression-free survival (PFS) or time to progression (TTP) could be a valid surrogate endpoint for overall survival (OS) in patients with limited-stage small-cell lung cancer (LS-SCLC) receiving combined chemoradiotherapy. METHODS: Literature searching was performed...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yin, Wang, Jianyang, Wang, Wenqing, Zhang, Tao, Zhao, Jingjing, Wang, Yu, Li, Yexiong, Wang, Luhua, Bi, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834538/
https://www.ncbi.nlm.nih.gov/pubmed/35155246
http://dx.doi.org/10.3389/fonc.2022.810580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834538/
https://www.ncbi.nlm.nih.gov/pubmed/35155246
http://dx.doi.org/10.3389/fonc.2022.810580

Ejemplares similares